GW&K Investment Management’s Edwards Lifesciences EW Stock Holding History

GW&K Investment Management’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$35K	Sell	436 -23	-5%	-$1.9K	﹤0.01%	630
2025 Q4	$39K	Buy	459 +27	+6%	+$2.22K	﹤0.01%	602
2025 Q3	$34K	Buy	432 +4	+0.9%	+$313	﹤0.01%	613
2025 Q2	$33K	Buy	428 +57	+15%	+$4.25K	﹤0.01%	583
2025 Q1	$27K	Sell	371 -39	-10%	-$2.79K	﹤0.01%	588
2024 Q4	$30K	Buy	410 +185	+82%	+$12.9K	﹤0.01%	546
2024 Q3	$15K	Sell	225 -79	-26%	-$5.74K	﹤0.01%	662
2024 Q2	$28K	Buy	304 +51	+20%	+$4.52K	﹤0.01%	508
2024 Q1	$24K	Buy	253 +71	+39%	+$5.96K	﹤0.01%	512
2023 Q4	$14K	Sell	182 -41	-18%	-$2.85K	﹤0.01%	584
2023 Q3	$15K	Buy	223 +28	+14%	+$2.25K	﹤0.01%	525
2023 Q2	$18K	Buy	+195	New	+$16.9K	﹤0.01%	489
2022 Q3	–	Sell	-1,099	Closed	-$105K	–	547
2022 Q2	$105K	Buy	1,099 +20	+2%	+$2.07K	﹤0.01%	355
2022 Q1	$127K	Buy	+1,079	New	+$121K	﹤0.01%	341

Other funds holding EW

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

GW&K Investment Management's EW Position: Q1 2026 in Review

GW&K Investment Management reduced its Edwards Lifesciences (EW) stake by 5% in Q1 2026, selling an estimated $1.9K and leaving 436 shares worth $35K. The position accounts for ﹤0.01% of the portfolio, ranked #630.

GW&K Investment Management first reported a position in EW in Q1 2022 and has held it in 14 quarters since. The position peaked at $127K in Q1 2022. 1,284 funds tracked by Wall St. Rank hold EW as of Q1 2026.

GW&K Investment Management held 436 shares of Edwards Lifesciences worth $35K as of Q1 2026.
GW&K Investment Management sold 23 Edwards Lifesciences shares in Q1 2026, an estimated $1.9K.
Edwards Lifesciences made up ﹤0.01% of GW&K Investment Management's portfolio in Q1 2026, its #630 holding.
GW&K Investment Management first reported a position in Edwards Lifesciences in Q1 2022 and has held it in 14 quarters since.
GW&K Investment Management's Edwards Lifesciences position peaked at $127K in Q1 2022.
1,284 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.

Based on GW&K Investment Management's 13F filing for Q1 2026, filed 13 May 2026.